Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 16 November 2017

Orphazyme A/S: Election of new members of the Board of Directors

Orphazyme A/S    

Published: 06:15 CET 16-11-2017 /GlobeNewswire /Source: Orphazyme A/S / : ORPHA /ISIN: DK0060911055

Orphazyme A/S: Election of new members of the Board of Directors

Company announcement

Orphazyme A/S

No. 4/2017

Ole Maaløes Vej 3

 

DK-2200 Copenhagen N

 

 

 

www.orphazyme.com

 

Company Registration No. 32266355

 

 

 

16 November 2017

 

On 16 November 2017, Orphazyme A/S ("Orphazyme") held an extraordinary general meeting at which Anders Hedegaard and Catherine Moukheibir were elected as new members of the Board of Directors as set out in the offering circular (the "Offering Circular") published on 6 November 2017 in connection with the Initial Public Offering and admission to trading and official listing of Orphazyme on Nasdaq Copenhagen A/S.

Anders Hedegaard is currently chief executive officer of GN Store Nord A/S and GN Hearing A/S and was previously CEO of Bavarian Nordic A/S. Anders Hedegaard holds a Master of Science in Chemical Engineering and Biochemistry from the Technical University of Denmark.

Catherine Moukheibir is currently chairman of the board of directors of MedDay Pharmaceuticals SA, member of the board of directors of Zealand Pharma A/S (publ) and Genkyotex SA (publ), as well as a member of the board of directors of Ablynx NV (publ) and Cerenis Therapeutics SA (publ). Catherine Moukheibir holds a Master in Economics and an MBA degree, both from Yale University.

As described in the Offering Circular, Martin Rahbek Kornum, Nanna Lüneborg and Patrick Krol resigned from the Board of Directors in connection with the extraordinary general meeting.

The Board of Directors is now composed as follows:

 

 

Composition of board committees

Name

Position

Audit committee

Remuneration committee

Nomination committee

Georges Gemayel

Chairman

 

 

Chair

Bo Jesper Hansen

Deputy Chairman

 

Chair

 

Anders Hedegaard

Member

 

Member

 

Catherine Moukheibir

Member

Chair

 

 

Martijn Kleijwegt

Member

Member

 

 

Martin Bonde

Member

 

 

Member

Rémi Droller

Member

 

Member

 

Sten Verland

Member

Member

 

Member

All members of the Board of Directors are considered independent for purposes of the current Danish Corporate Governance Recommendations.

For additional information, please contact 

 

Orphazyme

 

Anders Vadsholt, CFO

+45 28 98 90 55

 

About Orphazyme

Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. The Company was founded in 2009 based on early scientific discovery in heat shock proteins ("HSPs"). Since inception, the Company has translated scientific discovery into a late stage clinical development programme. The Company is headquartered in Copenhagen and currently has 30 employees.

The Company focuses on severe and mostly fatal diseases with a high unmet need, and with a particularly strong commitment to neuromuscular diseases and a group of severe genetic diseases called lysosomal storage diseases. The Company plans to pursue development of its lead candidate through to registration in the EU and the United States after which launch and commercialisation is expected to be undertaken by the Company.

The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis ("sIBM") and Amyotrophic Lateral Sclerosis ("ALS"), and two lysosomal storage diseases, Niemann Pick type C ("NPC") and Gaucher disease.



Orphazyme A/S - New members of the Board of Directors



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Orphazyme A/S, Ole Maaløes Vej 3, Copenhagen N 2200, Danmark
If you would like to unsubscribe and stop receiving these e-mails click here.